GlycoMimetics Promotes Dr. Eric Feldman to Chief Medical Officer
“Eric is internationally recognized for his work in the development of new therapies for the treatment of leukemias and related bone marrow disorders, and in the past two years, has established himself as a leader in our management group as well as in the trenches with our clinical operations team. Having spent his career dedicated to patients with hematologic malignancies, he is especially well positioned to lead our uproleselan program as it advances through Phase 3 clinical trials. In addition, his extensive clinical research background will serve us well as we drive forward other programs in our pipeline,” said
Before joining
Separately, Dr.
“Helen’s contributions to the Company have been invaluable, leading two programs to late-stage development, and creating important relationships with clinicians all over the world. We are grateful for her years of service to
About Uproleselan (GMI-1271)
Discovered and developed by
About
Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements include those relating to the potential benefits and impact of the Company’s drug candidates. Actual results may differ materially from those described in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005673/en/
Investor Contact:
Phone: 650-888-0902
Email: sannes@annesassociates.com
Media Contact:
Phone: 410-299-3310
Email: jamielacey@presscommpr.com
Source: